Symbols / PSNL Stock $5.52 +9.42% Personalis, Inc.

Healthcare • Diagnostics & Research • United States • NGM
PSNL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Mr. Christopher M. Hall
Exch · Country NGM · United States
Market Cap 577.30M
Enterprise Value 331.41M
Income -81.27M
Sales 69.65M
FCF (ttm) -42.98M
Book/sh 2.55
Cash/sh 2.29
Employees 259
Insider 10d —
IPO Jun 20, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.84
PEG —
P/S 8.29
P/B 2.16
P/C —
EV/EBITDA -4.25
EV/Sales 4.76
Quick Ratio 6.46
Current Ratio 6.76
Debt/Eq 16.85
LT Debt/Eq —
EPS (ttm) -0.91
EPS next Y -0.94
EPS Growth —
Revenue Growth 3.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-02-26
ROA -18.21%
ROE -35.02%
ROIC —
Gross Margin 22.65%
Oper. Margin -145.67%
Profit Margin -116.69%
Shs Outstand 104.68M
Shs Float 68.17M
Insider Own 27.02%
Instit Own 58.27%
Short Float 18.70%
Short Ratio 8.35
Short Interest 12.39M
52W High 11.50
vs 52W High -52.04%
52W Low 3.73
vs 52W Low 48.05%
Beta 2.21
Impl. Vol. 3.54%
Rel Volume 3.09
Avg Volume 1.56M
Volume 4.81M
Target (mean) $11.29
Tgt Median $11.00
Tgt Low $10.00
Tgt High $13.00
# Analysts 7
Recom Strong_buy
Prev Close $5.04
Price $5.51
Change 9.42%
About

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$11.29
Mean price target
2. Current target
$5.53
Latest analyst target
3. DCF / Fair value
$-7.39
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.53
Low
$10.00
High
$13.00
Mean
$11.29

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-05 main Morgan Stanley Equal-Weight → Equal-Weight $10
2026-02-27 main Needham Buy → Buy $12
2026-02-11 main BTIG Buy → Buy $13
2026-01-26 main Guggenheim Buy → Buy $13
2026-01-09 reit BTIG Buy → Buy $12
2025-12-02 main Morgan Stanley Equal-Weight → Equal-Weight $11
2025-11-11 main Morgan Stanley Equal-Weight → Equal-Weight $9
2025-11-11 main Guggenheim Buy → Buy $12
2025-11-11 main HC Wainwright & Co. Buy → Buy $13
2025-11-11 main BTIG Buy → Buy $12
2025-11-06 main HC Wainwright & Co. Buy → Buy $10
2025-11-05 main Needham Buy → Buy $10
2025-10-22 main BTIG Buy → Buy $11
2025-09-08 reit HC Wainwright & Co. Buy → Buy $9
2025-08-06 main HC Wainwright & Co. Buy → Buy $9
2025-05-07 main HC Wainwright & Co. Buy → Buy $9
2025-04-10 reit Needham Buy → Buy $7
2025-03-17 init Craig-Hallum — → Buy $8
2025-02-28 main Needham Buy → Buy $7
2025-02-28 reit HC Wainwright & Co. Buy → Buy $8
News
RSS: Latest PSNL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-13 TACHIBANA AARON Chief Operating Officer — 34,375 $0.00 $0
2026-03-13 HALL CHRISTOPHER M. Chief Executive Officer — 87,500 $0.00 $0
2026-03-13 CHEN RICHARD President — 46,875 $0.00 $0
2026-03-13 MOORE STEPHEN MICHAEL Officer — 28,125 $0.00 $0
2026-01-22 TACHIBANA AARON Chief Operating Officer — 1,201 $11.50 $13,812
2026-01-22 TACHIBANA AARON Chief Operating Officer — 1,201 $9.16 $11,001
2025-12-22 TEMPUS AI INC Beneficial Owner of more than 10% of a Class of Security — 320,267 $7.67 $2,739,181
2025-11-25 TACHIBANA AARON Chief Operating Officer — 103,668 $10.78 $1,117,541
2025-11-25 TACHIBANA AARON Chief Operating Officer — 103,668 $9.16 $949,599
2025-11-03 HALL CHRISTOPHER M. Chief Executive Officer — 29,612 $8.99 $266,212
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
69.65
-17.69%
84.61
+15.15%
73.48
+12.97%
65.05
Operating Revenue
68.33
-19.13%
84.49
+15.61%
73.08
+13.07%
64.64
Cost Of Revenue
53.87
-6.78%
57.79
+4.55%
55.27
+6.92%
51.70
Reconciled Cost Of Revenue
53.87
-6.78%
57.79
+4.55%
55.27
+6.92%
51.70
Gross Profit
15.78
-41.19%
26.82
+47.33%
18.21
+36.39%
13.35
Operating Expense
103.83
+9.19%
95.09
-16.95%
114.50
-11.16%
128.88
Research And Development
50.26
+2.78%
48.91
-24.50%
64.78
-0.21%
64.91
Selling General And Administration
53.57
+15.99%
46.19
-7.12%
49.73
-22.27%
63.97
Total Expenses
157.71
+3.16%
152.88
-9.95%
169.78
-5.98%
180.58
Operating Income
-88.06
-28.99%
-68.27
+29.11%
-96.29
+16.65%
-115.53
Total Operating Income As Reported
-88.06
-28.99%
-68.27
+37.90%
-109.94
+4.84%
-115.53
EBITDA
-71.00
-0.99%
-70.30
+27.38%
-96.81
+7.49%
-104.64
Normalized EBITDA
-71.00
-0.99%
-70.30
+15.47%
-83.17
+20.52%
-104.64
Reconciled Depreciation
10.05
-8.18%
10.94
-3.14%
11.30
+33.97%
8.43
EBIT
-81.04
+0.24%
-81.24
+24.85%
-108.10
+4.40%
-113.07
Total Unusual Items
—
0.00
+100.00%
-13.64
0.00
Total Unusual Items Excluding Goodwill
—
0.00
+100.00%
-13.64
0.00
Special Income Charges
—
0.00
+100.00%
-13.64
0.00
Impairment Of Capital Assets
—
0.00
-100.00%
5.57
0.00
Restructuring And Mergern Acquisition
—
0.00
-100.00%
8.08
0.00
Net Income
-81.27
+0.02%
-81.28
+24.94%
-108.30
+4.43%
-113.31
Pretax Income
-81.25
+0.02%
-81.27
+24.90%
-108.21
+4.47%
-113.28
Net Non Operating Interest Income Expense
6.95
+26.69%
5.49
-5.27%
5.79
+163.83%
2.19
Interest Expense Non Operating
0.20
+754.17%
0.02
-78.18%
0.11
-45.27%
0.20
Net Interest Income
6.95
+26.69%
5.49
-5.27%
5.79
+163.83%
2.19
Interest Expense
0.20
+754.17%
0.02
-78.18%
0.11
-45.27%
0.20
Interest Income Non Operating
7.16
+29.85%
5.51
-6.63%
5.90
+146.29%
2.40
Interest Income
7.16
+29.85%
5.51
-6.63%
5.90
+146.29%
2.40
Other Income Expense
-0.14
+99.23%
-18.48
-4.38%
-17.71
-29132.79%
0.06
Other Non Operating Income Expenses
-0.14
+99.23%
-18.48
-354.40%
-4.07
-6768.85%
0.06
Tax Provision
0.02
+16.67%
0.02
-78.31%
0.08
+107.50%
0.04
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-81.27
+0.02%
-81.28
+24.94%
-108.30
+4.43%
-113.31
Net Income From Continuing Operation Net Minority Interest
-81.27
+0.02%
-81.28
+24.94%
-108.30
+4.43%
-113.31
Net Income From Continuing And Discontinued Operation
-81.27
+0.02%
-81.28
+24.94%
-108.30
+4.43%
-113.31
Net Income Continuous Operations
-81.27
+0.02%
-81.28
+24.94%
-108.30
+4.43%
-113.31
Normalized Income
-81.27
+0.02%
-81.28
+14.13%
-94.65
+16.47%
-113.31
Net Income Common Stockholders
-81.27
+0.02%
-81.28
+24.94%
-108.30
+4.43%
-113.31
Diluted EPS
—
-1.37
+39.11%
-2.25
+9.27%
-2.48
Basic EPS
—
-1.37
+39.11%
-2.25
+9.27%
-2.48
Basic Average Shares
—
59.25
+22.99%
48.18
+5.41%
45.70
Diluted Average Shares
—
59.25
+22.99%
48.18
+5.41%
45.70
Diluted NI Availto Com Stockholders
-81.27
+0.02%
-81.28
+24.94%
-108.30
+4.43%
-113.31
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
334.16
+23.64%
270.27
+20.07%
225.10
-23.10%
292.70
Current Assets
267.95
+31.99%
203.01
+38.35%
146.74
-26.52%
199.70
Cash Cash Equivalents And Short Term Investments
239.95
+29.70%
185.01
+62.03%
114.18
-31.90%
167.66
Cash And Cash Equivalents
124.25
+35.91%
91.42
+60.42%
56.98
-36.06%
89.13
Cash Equivalents
119.33
+32.20%
90.26
+69.24%
53.34
-36.14%
83.51
Cash Financial
4.92
+327.00%
1.15
-68.43%
3.65
-35.01%
5.62
Other Short Term Investments
115.71
+23.63%
93.59
+63.64%
57.20
-27.17%
78.53
Receivables
16.20
+99.05%
8.14
-54.09%
17.73
+6.54%
16.64
Accounts Receivable
16.20
+99.05%
8.14
-54.09%
17.73
+6.54%
16.64
Inventory
5.26
+32.22%
3.98
-29.77%
5.66
-11.33%
6.38
Raw Materials
5.26
+32.22%
3.98
-29.77%
5.66
-11.33%
6.38
Prepaid Assets
—
—
—
—
Current Deferred Assets
0.89
-54.81%
1.96
-59.21%
4.81
+118.08%
2.21
Other Current Assets
5.65
+43.90%
3.93
-9.95%
4.36
-35.94%
6.81
Total Non Current Assets
66.21
-1.55%
67.25
-14.17%
78.36
-15.75%
93.00
Net PPE
59.93
-7.41%
64.73
-13.95%
75.22
-14.93%
88.42
Gross PPE
113.84
+2.78%
110.77
-1.88%
112.89
-2.13%
115.34
Accumulated Depreciation
-53.91
-17.10%
-46.04
-22.22%
-37.67
-39.89%
-26.93
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
56.98
+9.88%
51.86
+2.21%
50.74
+14.01%
44.50
Construction In Progress
0.06
-93.77%
0.90
-74.20%
3.48
-12.63%
3.99
Other Properties
15.12
-8.11%
16.45
-7.84%
17.85
-32.58%
26.48
Leases
41.69
+0.32%
41.56
+1.83%
40.81
+1.09%
40.37
Other Non Current Assets
6.28
+148.61%
2.53
-19.48%
3.14
-31.60%
4.59
Total Liabilities Net Minority Interest
72.98
+8.42%
67.31
-29.63%
95.66
+28.29%
74.56
Current Liabilities
39.63
+27.32%
31.13
-34.10%
47.23
+42.57%
33.13
Payables And Accrued Expenses
17.19
+120.46%
7.80
-47.74%
14.92
+1.66%
14.68
Payables
12.99
+103.05%
6.40
-57.12%
14.92
+14.97%
12.98
Accounts Payable
12.99
+103.05%
6.40
-57.12%
14.92
+16.07%
12.85
Current Accrued Expenses
4.20
+200.00%
1.40
0.00
-100.00%
1.70
Pensionand Other Post Retirement Benefit Plans Current
7.34
-17.04%
8.85
-32.62%
13.13
+37.44%
9.55
Total Tax Payable
—
—
0.04
-69.92%
0.12
Current Debt And Capital Lease Obligation
8.08
-13.70%
9.37
-0.45%
9.41
+23.63%
7.61
Current Debt
1.19
-28.70%
1.67
+1.40%
1.65
-25.79%
2.22
Other Current Borrowings
1.19
-28.70%
1.67
+1.40%
1.65
-25.79%
2.22
Current Capital Lease Obligation
6.89
-10.45%
7.70
-0.84%
7.76
+43.96%
5.39
Current Deferred Liabilities
1.56
-49.61%
3.10
-5.72%
3.29
+154.10%
1.29
Current Deferred Revenue
1.56
-49.61%
3.10
-5.72%
3.29
+154.10%
1.29
Other Current Liabilities
5.46
+170.38%
2.02
-68.90%
6.49
—
Total Non Current Liabilities Net Minority Interest
33.35
-7.84%
36.19
-25.27%
48.42
+16.88%
41.43
Long Term Debt And Capital Lease Obligation
31.87
-8.65%
34.88
-8.97%
38.32
-6.63%
41.04
Long Term Capital Lease Obligation
31.87
-8.65%
34.88
-8.97%
38.32
-6.63%
41.04
Other Non Current Liabilities
1.48
+13.81%
1.30
-74.75%
5.16
+1226.74%
0.39
Stockholders Equity
261.19
+28.69%
202.96
+56.79%
129.44
-40.66%
218.14
Common Stock Equity
261.19
+28.69%
202.96
+56.79%
129.44
-40.66%
218.14
Capital Stock
0.01
+11.11%
0.01
+80.00%
0.01
+0.00%
0.01
Common Stock
0.01
+11.11%
0.01
+80.00%
0.01
+0.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
102.48
+20.32%
85.17
+68.72%
50.48
+8.08%
46.71
Ordinary Shares Number
102.48
+20.32%
85.17
+68.72%
50.48
+8.08%
46.71
Additional Paid In Capital
892.33
+18.51%
752.96
+25.84%
598.36
+3.26%
579.46
Retained Earnings
-631.26
-14.78%
-549.99
-17.34%
-468.71
-30.05%
-360.41
Gains Losses Not Affecting Retained Earnings
0.10
+552.17%
-0.02
+89.64%
-0.22
+75.66%
-0.91
Other Equity Adjustments
0.10
+552.17%
-0.02
+89.64%
-0.22
+75.66%
-0.91
Total Equity Gross Minority Interest
261.19
+28.69%
202.96
+56.79%
129.44
-40.66%
218.14
Total Capitalization
261.19
+28.69%
202.96
+56.79%
129.44
-40.66%
218.14
Working Capital
228.32
+32.83%
171.89
+72.74%
99.51
-40.26%
166.57
Invested Capital
262.38
+28.22%
204.63
+56.10%
131.09
-40.51%
220.36
Total Debt
39.95
-9.72%
44.25
-7.29%
47.73
-1.90%
48.65
Capital Lease Obligations
38.76
-8.97%
42.58
-7.60%
46.08
-0.75%
46.43
Net Tangible Assets
261.19
+28.69%
202.96
+56.79%
129.44
-40.66%
218.14
Tangible Book Value
261.19
+28.69%
202.96
+56.79%
129.44
-40.66%
218.14
Derivative Product Liabilities
—
0.00
-100.00%
4.94
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-74.95
-65.99%
-45.15
+19.74%
-56.26
+19.90%
-70.23
Cash Flow From Continuing Operating Activities
-74.95
-65.99%
-45.15
+19.74%
-56.26
+19.90%
-70.23
Net Income From Continuing Operations
-81.27
+0.02%
-81.28
+24.94%
-108.30
+4.43%
-113.31
Depreciation Amortization Depletion
10.05
-8.18%
10.94
-3.14%
11.30
+33.97%
8.43
Depreciation And Amortization
10.05
-8.18%
10.94
-3.14%
11.30
+33.97%
8.43
Other Non Cash Items
1.03
-30.76%
1.49
-73.44%
5.62
+23.48%
4.55
Stock Based Compensation
9.43
-11.76%
10.69
-23.95%
14.05
-27.70%
19.43
Asset Impairment Charge
—
0.00
-100.00%
5.57
0.00
Operating Gains Losses
—
18.27
+353.79%
4.03
—
Gain Loss On Investment Securities
—
18.27
+353.79%
4.03
—
Change In Working Capital
-10.19
-293.25%
-2.59
-119.23%
13.48
+27.06%
10.61
Change In Receivables
-8.06
-184.08%
9.59
+981.43%
-1.09
-159.62%
1.82
Changes In Account Receivables
-8.06
-184.08%
9.59
+981.43%
-1.09
-159.62%
1.82
Change In Inventory
-0.20
-104.61%
4.42
+328.80%
-1.93
+35.14%
-2.98
Change In Prepaid Assets
-2.22
-295.26%
1.14
-69.61%
3.75
+674.38%
0.48
Change In Payables And Accrued Expense
6.86
+160.54%
-11.32
-291.30%
5.92
+267.70%
1.61
Change In Accrued Expense
2.31
+196.04%
-2.40
-423.58%
0.74
+150.17%
-1.48
Change In Payable
4.55
+150.99%
-8.92
-272.34%
5.18
+67.63%
3.09
Change In Account Payable
4.55
+150.99%
-8.92
-272.34%
5.18
+67.63%
3.09
Change In Other Working Capital
-1.54
+62.63%
-4.12
-169.15%
5.95
+318.98%
-2.72
Change In Other Current Liabilities
-5.02
-117.79%
-2.31
-360.75%
0.88
-92.87%
12.39
Investing Cash Flow
-22.57
+35.65%
-35.07
-367.72%
13.10
-75.07%
52.54
Cash Flow From Continuing Investing Activities
-22.57
+35.65%
-35.07
-367.72%
13.10
-75.07%
52.54
Net PPE Purchase And Sale
-4.50
-230.93%
-1.36
+87.53%
-10.91
+78.13%
-49.90
Purchase Of PPE
-4.50
-180.97%
-1.60
+85.31%
-10.91
+78.13%
-49.90
Sale Of PPE
0.00
-100.00%
0.24
0.00
—
Capital Expenditure
-4.50
-180.97%
-1.60
+85.31%
-10.91
+78.13%
-49.90
Net Investment Purchase And Sale
-18.06
+46.41%
-33.71
-240.39%
24.01
-76.56%
102.43
Purchase Of Investment
-210.17
-72.69%
-121.71
-17.09%
-103.94
+14.44%
-121.49
Sale Of Investment
192.11
+118.31%
88.00
-31.23%
127.95
-42.86%
223.92
Financing Cash Flow
130.34
+13.66%
114.67
+939.54%
11.03
+707.54%
1.37
Cash Flow From Continuing Financing Activities
130.34
+13.66%
114.67
+939.54%
11.03
+707.54%
1.37
Net Issuance Payments Of Debt
0.58
+151.77%
-1.13
-749.43%
0.17
+115.83%
-1.10
Issuance Of Debt
2.59
0.00
-100.00%
3.44
+187.94%
1.19
Repayment Of Debt
-2.00
-77.17%
-1.13
+65.38%
-3.26
-42.35%
-2.29
Long Term Debt Issuance
2.59
0.00
-100.00%
3.44
+187.94%
1.19
Long Term Debt Payments
-2.00
-77.17%
-1.13
+65.38%
-3.26
-42.35%
-2.29
Net Long Term Debt Issuance
0.58
+151.77%
-1.13
-749.43%
0.17
+115.83%
-1.10
Net Common Stock Issuance
126.80
+29.62%
97.82
+2684.63%
3.51
0.00
Proceeds From Stock Option Exercised
3.15
-83.63%
19.21
+161.55%
7.34
+197.93%
2.46
Net Other Financing Charges
-0.19
+84.63%
-1.23
—
—
Changes In Cash
32.82
-4.73%
34.45
+207.24%
-32.13
-96.74%
-16.33
Effect Of Exchange Rate Changes
0.01
+127.27%
-0.02
-37.50%
-0.02
+87.40%
-0.13
Beginning Cash Position
93.20
+58.58%
58.77
-35.35%
90.92
-15.33%
107.38
End Cash Position
126.03
+35.22%
93.20
+58.58%
58.77
-35.35%
90.92
Free Cash Flow
-79.45
-69.94%
-46.75
+30.39%
-67.17
+44.09%
-120.13
Interest Paid Supplemental Data
—
—
0.00
0.00
Income Tax Paid Supplemental Data
0.02
-39.47%
0.04
-40.63%
0.06
+36.17%
0.05
Amortization Of Securities
-3.99
-49.64%
-2.67
-33.35%
-2.00
-3608.77%
0.06
Common Stock Issuance
126.80
+29.62%
97.82
+2684.63%
3.51
0.00
Issuance Of Capital Stock
126.80
+29.62%
97.82
+2684.63%
3.51
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category